General MedicationsSUBCUTANEOUSStandard

ZEMBRACE SYMTOUCH

SUMATRIPTAN SUCCINATE

Standard Dose

EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview ZEMBRACE SYMTOUCH is listed in Drugs@FDA under application 208223 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN SUCCINATE Form and strength SOLUTION;SUBCUTANEOUS - EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) Sponsor TONIX MEDS Submission history Latest submission status date: 2019-06-10 00:00:00.

Structured Monograph

Clinical summary

Approval overview ZEMBRACE SYMTOUCH is listed in Drugs@FDA under application 208223 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN SUCCINATE Form and strength SOLUTION;SUBCUTANEOUS - EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) Sponsor TONIX MEDS Submission history Latest submission status date: 2019-06-10 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.